Molecular Partners to present at the 34th Annual J.P. Morgan Healthcare Conference Dienstag, 12. Januar 2016 - 07:08
 |
MEDIA RELEASE |
| Media Release (PDF) |
Molecular Partners to present at the 34th Annual J.P. Morgan Healthcare Conference |
Zurich-Schlieren, January 12, 2016. Molecular Partners AG (MOLN) today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday January 13, 2016 at 5:00 PM Pacific Standard Time (8:00 PM Eastern Time). The presentation, followed by a Q&A session, will be hosted by Dr. Christian Zahnd, CEO of Molecular Partners.
The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A copy of the presentation handout as well as a replay of the webcast will be made available on the company's website www.molecularpartners.com under the Investors section. The replay will be available for 30 days following the presentation.
About Molecular Partners AG Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new, powerful class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners, go to: www.molecularpartners.com.
For further details, please contact: Dr. Christian Zahnd, CEO christian.zahnd@molecularpartners.com Tel: +41 (0) 44 755 77 00
Andreas Emmenegger, CFO andreas.emmenegger@molecularpartners.com Tel: +41 (0) 44 755 77 00
Rolf Schläpfer Hirzel.Neef.Schmid.Counselors rolf.schlaepfer@konsulenten.ch Tel: +41 (0) 43 344 42 42 |
Legal Notice This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements, assessments or intentions. |